Deutsche Bank AG Has $3.18 Million Holdings in Protagonist Therapeutics, Inc. $PTGX

Deutsche Bank AG lessened its position in shares of Protagonist Therapeutics, Inc. (NASDAQ:PTGX) by 52.4% during the 1st quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor owned 65,695 shares of the company’s stock after selling 72,237 shares during the quarter. Deutsche Bank AG owned approximately 0.11% of Protagonist Therapeutics worth $3,177,000 as of its most recent filing with the Securities and Exchange Commission.

Several other institutional investors also recently modified their holdings of the company. Bank of Montreal Can grew its holdings in shares of Protagonist Therapeutics by 4.5% during the 4th quarter. Bank of Montreal Can now owns 6,250 shares of the company’s stock worth $241,000 after purchasing an additional 270 shares in the last quarter. GF Fund Management CO. LTD. grew its holdings in shares of Protagonist Therapeutics by 22.0% during the 1st quarter. GF Fund Management CO. LTD. now owns 1,526 shares of the company’s stock worth $74,000 after purchasing an additional 275 shares in the last quarter. PNC Financial Services Group Inc. grew its holdings in shares of Protagonist Therapeutics by 38.2% during the 1st quarter. PNC Financial Services Group Inc. now owns 1,992 shares of the company’s stock worth $96,000 after purchasing an additional 551 shares in the last quarter. GAMMA Investing LLC grew its holdings in shares of Protagonist Therapeutics by 153.3% during the 1st quarter. GAMMA Investing LLC now owns 1,203 shares of the company’s stock worth $58,000 after purchasing an additional 728 shares in the last quarter. Finally, State of Wyoming grew its holdings in shares of Protagonist Therapeutics by 11.9% during the 4th quarter. State of Wyoming now owns 7,832 shares of the company’s stock worth $302,000 after purchasing an additional 832 shares in the last quarter. Institutional investors and hedge funds own 98.63% of the company’s stock.

Protagonist Therapeutics Price Performance

Shares of PTGX stock opened at $56.21 on Tuesday. The firm has a market cap of $3.50 billion, a price-to-earnings ratio of 80.30 and a beta of 2.33. The stock’s fifty day simple moving average is $54.12 and its 200 day simple moving average is $48.15. Protagonist Therapeutics, Inc. has a one year low of $33.31 and a one year high of $60.60.

Protagonist Therapeutics (NASDAQ:PTGX) last posted its quarterly earnings data on Wednesday, August 6th. The company reported ($0.55) EPS for the quarter, missing analysts’ consensus estimates of ($0.53) by ($0.02). The business had revenue of $5.55 million during the quarter, compared to analyst estimates of $8.32 million. Protagonist Therapeutics had a return on equity of 8.12% and a net margin of 24.88%. On average, research analysts anticipate that Protagonist Therapeutics, Inc. will post 2.43 earnings per share for the current year.

Analysts Set New Price Targets

Several analysts have recently weighed in on the company. JMP Securities lifted their price objective on Protagonist Therapeutics from $67.00 to $69.00 and gave the stock a “market outperform” rating in a report on Thursday, August 7th. HC Wainwright reaffirmed a “buy” rating and issued a $80.00 price target on shares of Protagonist Therapeutics in a research note on Tuesday, June 3rd. Wall Street Zen raised Protagonist Therapeutics from a “sell” rating to a “hold” rating in a research note on Sunday, June 8th. Finally, Citigroup reaffirmed an “outperform” rating on shares of Protagonist Therapeutics in a research note on Thursday, August 7th. Two research analysts have rated the stock with a hold rating, seven have assigned a buy rating and one has assigned a strong buy rating to the stock. According to data from MarketBeat.com, the company currently has an average rating of “Moderate Buy” and a consensus price target of $67.20.

Insiders Place Their Bets

In other Protagonist Therapeutics news, insider Arturo Md Molina sold 10,000 shares of the business’s stock in a transaction on Tuesday, June 10th. The stock was sold at an average price of $57.03, for a total value of $570,300.00. Following the transaction, the insider owned 83,892 shares of the company’s stock, valued at approximately $4,784,360.76. The trade was a 10.65% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, CEO Dinesh V. Ph D. Patel sold 22,065 shares of the business’s stock in a transaction on Tuesday, July 22nd. The stock was sold at an average price of $55.05, for a total value of $1,214,678.25. Following the completion of the transaction, the chief executive officer directly owned 548,538 shares in the company, valued at approximately $30,197,016.90. This represents a 3.87% decrease in their position. The disclosure for this sale can be found here. In the last three months, insiders sold 72,859 shares of company stock worth $4,020,877. Insiders own 4.90% of the company’s stock.

Protagonist Therapeutics Profile

Protagonist Therapeutics, Inc, a biopharmaceutical company, develops peptide-based drugs for hematology and blood disorders, and inflammatory and immunomodulatory diseases. It is developing Rusfertide (PTG-300), an injectable hepcidin mimetic that completed phase 2 clinical trials for the treatment of polycythemia vera and other blood disorders; and JNJ-2113, an orally delivered investigational drug to block biological pathways that completed phase 2b clinical trials for the treatment of moderate-to-severe plaque psoriasis; and PN-943, an orally delivered, gut-restricted alpha 4 beta 7 specific integrin antagonist completed a phase 2 clinical trials in patients with moderate to severe ulcerative colitis.